For adults diagnosed with early-stage (stage 1-3) EGFR+ non-small cell **lung cancer** (NSCLC) who are discussing treatment options with their healthcare team

TAGRISSO is a prescription oral treatment used to help prevent non-small cell lung cancer with certain abnormal EGFR gene(s) from coming back after your tumor has been removed by surgery.

EGFR+ is epidermal growth factor receptor mutation-positive.

Select Safety Information

TAGRISSO may cause serious side effects, including severe lung problems, heart, eye, and skin problems, inflammation of the blood vessels in your skin, and blood and bone marrow problems. Some may lead to death. The most common side effects of TAGRISSO when given alone are low white blood cell counts, low platelet counts, low red blood cell counts (anemia), diarrhea, rash, muscle, bone, or joint pain, changes in your nails, dry skin, mouth sores, and tiredness. These are not all the possible side effects.

Please see full Important Safety Information on pages 6 to 9 and complete Prescribing Information, including Patient Information for TAGRISSO.

TAGRISSO®
osimertinib

If you have early-stage (stage 1-3) NSCLC and are having surgery to remove your tumor...

Treatment may help **prevent your cancer from coming back**

Why is it important to have a treatment plan after surgery?

Even after surgery, cancer may be able to return. Having your doctor test your tumor for **biomarkers** and create a personalized treatment plan for you may help prevent your cancer from coming back.

What is a biomarker and how do I get tested?

Mutations, sometimes called biomarkers, may be present in your type of lung cancer and could cause your cancer to grow and spread. It's important to test your cancer for biomarkers as early as possible, so you and your doctor can use your results to help decide your treatment plan.

Biomarker testing can be done at diagnosis or any time in your treatment journey. Your doctor can test the tissue that was removed during surgery or do a biopsy to remove tissue from your tumor. Your surgeon may test your tumor or refer you to a medical oncologist for testing.

Ask your surgeon about biomarker testing and schedule your appointment.

Please see full Important Safety Information on pages 6 to 9 and complete Prescribing Information, including Patient Information for TAGRISSO.

TAGRISSO® osimertinib

One common and important biomarker found in NSCLC are mutations in the epidermal growth factor receptor or EGFR

Biomarker testing can identify if your non-small cell lung cancer has an EGFR mutation. If so, it's considered **EGFR+ NSCLC**.

Knowing your biomarker status can help your doctor create a treatment plan designed for your type of cancer.

About **1** in **5**

people with stage 1-3 NSCLC have cancer that tests positive for an EGFR mutation.*

If an EGFR mutation is driving your lung cancer, you may be able to treat it by targeting that specific mutation.

Why TAGRISSO?

TAGRISSO is a targeted therapy, not the same as immunotherapy or standard chemotherapy.

It's a once-daily pill approved to treat certain patients with EGFR+ NSCLC and help prevent your lung cancer from coming back after your tumor has been removed by surgery.†

TAGRISSO is designed to target and block certain mutated EGFR genes found on cancer cells that are a driving cause behind your cancer growing and spreading.

*Based on 2 studies: The first study included 1007 cases of lung cancer. They tested 987 cases for specific EGFR mutations and other mutations in the EGFR gene. Out of those 987 cases, 331 had stage 1-3 NSCLC. The second study analyzed tumors that were surgically removed from 1118 patients with stage 1-3 NSCLC for specific EGFR mutations.

†For tumors with EGFR exon 19 deletions or exon 21 L858R mutations.

Select Safety Information

TAGRISSO may cause serious side effects, including severe lung problems, heart, eye, and skin problems, inflammation of the blood vessels in your skin, and blood and bone marrow problems. Some may lead to death. The most common side effects of TAGRISSO when given alone are low white blood cell counts, low platelet counts, low red blood cell counts (anemia), diarrhea, rash, muscle, bone, or joint pain, changes in your nails, dry skin, mouth sores, and tiredness. These are not all the possible side effects.

Please see full Important Safety Information on pages 6 to 9 and complete Prescribing Information, including Patient Information for TAGRISSO.

TAGRISSO® osimertinib

TAGRISSO may help prevent your cancer from coming back after surgery...

TAGRISSO was studied in a clinical trial that included 682 adults with stages 1B, 2, and 3A EGFR+ NSCLC whose tumors had been removed by surgery and who may have had chemotherapy after their surgery. All adults in the clinical trial were treated with either TAGRISSO (339 people) or placebo (no active medicine) (343 people).

The main goal of the trial was **disease-free survival** (DFS), which is the length of time people are cancer free after starting treatment. A secondary goal of the trial was **overall survival** (OS), which is the length of time people are alive after starting treatment.

In the clinical trial, **TAGRISSO was taken for 3 years or until their disease came back or their doctor stopped treatment**

Select Safety Information

TAGRISSO may cause serious side effects, including severe lung problems, heart, eye, and skin problems, inflammation of the blood vessels in your skin, and blood and bone marrow problems. Some may lead to death. The most common side effects of TAGRISSO when given alone are low white blood cell counts, low platelet counts, low red blood cell counts (anemia), diarrhea, rash, muscle, bone, or joint pain, changes in your nails, dry skin, mouth sores, and tiredness. These are not all the possible side effects.

Please see full Important Safety Information on pages 6 to 9 and complete Prescribing Information, including Patient Information for TAGRISSO.

TAGRISSO® osimertinib

...And may help you **LIVE LONGER**



In the clinical trial, people with stages 1B, 2, and 3A EGFR+ NSCLC who were treated with TAGRISSO following surgery were **80% less likely to have their cancer come back** or die vs those who took no active medicine.

- At time of follow-up, 89% (302 of 339) of people given TAGRISSO didn't have their cancer come back and were still alive compared to 54% (184 of 343) of people given no active medicine

In the same clinical trial, people with stages 1B, 2, and 3A EGFR+ NSCLC taking TAGRISSO were **twice as likely to survive** vs people who took no active medicine.

People taking TAGRISSO were **51% less likely to die** than those who took no active medicine.

- When patients were followed up for overall survival, 88% (297 of 339) of people given TAGRISSO were still alive compared to 76% (261 of 343) of people given no active medicine

Select Safety Information

TAGRISSO may cause serious side effects, including severe lung problems, heart, eye, and skin problems, inflammation of the blood vessels in your skin, and blood and bone marrow problems. Some may lead to death. The most common side effects of TAGRISSO when given alone are low white blood cell counts, low platelet counts, low red blood cell counts (anemia), diarrhea, rash, muscle, bone, or joint pain, changes in your nails, dry skin, mouth sores, and tiredness. These are not all the possible side effects.

Please see full Important Safety Information on pages 6 to 9 and complete Prescribing Information, including Patient Information for TAGRISSO.

TAGRISSO® osimertinib

Important Safety Information

TAGRISSO may cause serious side effects, including:

Lung problems.

TAGRISSO may cause severe lung problems that may lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your healthcare provider right away if you have any new or worsening lung symptoms, including trouble breathing, shortness of breath, cough, or fever

Heart problems, including heart failure.

TAGRISSO may cause heart problems that may lead to death. Your healthcare provider should check your heart function before you start taking TAGRISSO and during treatment as needed. Tell your healthcare provider right away if you have any of the following signs and symptoms of a heart problem: feeling like your heart is pounding or racing, shortness of breath, swelling of your ankles and feet, dizziness, feeling lightheaded, or feeling faint

Eye problems.

TAGRISSO may cause eye problems. Tell your healthcare provider right away if you have symptoms of eye problems which may include watery eyes, sensitivity to light, eye pain, eye redness, or vision changes. Your healthcare provider may send you to see an eye specialist (ophthalmologist) if you get eye problems with TAGRISSO

Skin problems.

TAGRISSO may cause skin problems. Tell your healthcare provider right away if you develop skin reactions that look like rings (target lesions), severe blistering or peeling of the skin

Inflammation of the blood vessels in your skin.

TAGRISSO may cause blood vessel problems in your skin. Tell your healthcare provider right away if you develop purple spots or redness of the skin that does not fade in color when pressed (non-blanching) on your lower arms, lower legs, or buttocks or large hives on the main part of your body (trunk) that do not go away within 24 hours and look bruised

Blood and bone marrow problems.

TAGRISSO may cause a condition where your bone marrow cannot make enough new blood cells (aplastic anemia), and which may lead to death. Your healthcare provider will monitor your blood cell counts before you start and during treatment with TAGRISSO. **Tell your healthcare provider right away** if you develop any signs and symptoms of blood and bone marrow problems, including a new fever or fever that does not go away (≥100.4 °F), easy bruising or bleeding that will not stop, unusually pale skin, infection, tiredness, or weakness

Please see additional Important Safety Information on pages 7 to 9 and complete Prescribing Information, including Patient Information for TAGRISSO.

TAGRISSO® osimertinib

Important Safety Information (continued)

Before taking TAGRISSO, tell your healthcare provider about all of your medical conditions, including if you:

- have lung or breathing problems other than your lung cancer
- have heart problems, including a condition called long QTc syndrome
- have problems with your electrolytes, such as sodium, potassium, calcium or magnesium
- have a history of eye problems
- are pregnant or plan to become pregnant. TAGRISSO can harm your unborn baby. Tell your healthcare provider right away if you become pregnant during treatment with TAGRISSO or think you may be pregnant
  - **Females** who are able to become pregnant should have a pregnancy test before starting treatment with TAGRISSO. You should use effective birth control (contraception) during treatment with TAGRISSO and for 6 weeks after the last dose of TAGRISSO
  - **Males** who have female partners that are able to become pregnant should use effective birth control during treatment with TAGRISSO and for 4 months after the last dose of TAGRISSO
- females who are breastfeeding or plan to breastfeed. It is not known if TAGRISSO passes into your breast milk. Do not breastfeed during treatment with TAGRISSO and for 2 weeks after your last dose of TAGRISSO. Talk to your healthcare provider about the best way to feed your baby during this time

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements. Especially tell your healthcare provider if you take a heart or blood pressure medicine

Please see additional Important Safety Information on pages 6, 8, and 9 and complete Prescribing Information, including Patient Information for TAGRISSO.

TAGRISSO® osimertinib

Important Safety Information (continued)

The most common side effects of TAGRISSO when given alone include:

low white blood cell counts



low platelet counts

low red blood cell counts (anemia)

diarrhea

rash

muscle, bone, or joint pain

changes in your nails, including: redness, tenderness, pain, inflammation, brittleness, separation from nailbed, and shedding of nail

dry skin

mouth sores

tiredness

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of TAGRISSO. For more information, ask your healthcare provider or pharmacist.



Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see additional Important Safety Information on pages 6, 7, and 9 and complete Prescribing Information, including Patient Information for TAGRISSO.

TAGRISSO® osimertinib

Important Safety Information (continued)

What is TAGRISSO?

TAGRISSO is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that has certain abnormal epidermal growth factor receptor (EGFR) gene(s):

- to help prevent your lung cancer from coming back after your tumor(s) has been removed by surgery

Your healthcare provider will perform a test to make sure that TAGRISSO is right for you.

It is not known if TAGRISSO is safe and effective in children.

MY **NOTES**

My next appointment is: _____

My Oncologist's contact info: _____

Other important contacts: _____

Date for biomarker testing: _____

Biomarker test results: _____

Treatment options to research: _____

Organizations/websites of interest: _____

Please see additional Important Safety Information on pages 6 to 8 and complete Prescribing Information, including Patient Information for TAGRISSO.

TAGRISSO® osimertinib

Support is in reach

As you continue treating your early-stage (stage 1-3) lung cancer, learn as much as you can about your diagnosis and treatment plan.

Sign up for a free information kit

Scan the code to sign up and learn more about early-stage EGFR+ NSCLC and treatment with TAGRISSO

Indication and Select Safety Information

TAGRISSO is a once-daily prescription pill used for adults to help prevent non-small cell lung cancer with certain abnormal EGFR gene(s) from coming back after removal by surgery.

TAGRISSO may cause serious side effects, including severe lung problems, heart, eye, and skin problems, inflammation of the blood vessels in your skin, and blood and bone marrow problems. Some may lead to death. The most common side effects of TAGRISSO when given alone are low white blood cell counts, low platelet counts, low red blood cell counts (anemia), diarrhea, rash, muscle, bone, or joint pain, changes in your nails, dry skin, mouth sores, and tiredness. These are not all the possible side effects.

Please see full Important Safety Information on pages 6 to 9 and complete Prescribing Information, including Patient Information for TAGRISSO.

You may report side effects related to AstraZeneca products.

AstraZeneca

This product information is intended for US consumers only.
TAGRISSO is a registered trademark of the AstraZeneca group of companies.
©2025 AstraZeneca. All rights reserved. US-98317 Last Updated 5/25

TAGRISSO® osimertinib